百克生物跌2.42% 2021上市募15亿中信证券保荐

Core Viewpoint - 百克生物's stock price has fallen to 19.37 yuan, reflecting a decline of 2.42%, indicating the stock is currently in a state of underperformance since its IPO [1]. Group 1: IPO and Financials - 百克生物 was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 25, 2021, with an initial public offering (IPO) of 41.2841 million shares, representing 10% of the total shares post-issue, at a price of 36.35 yuan per share [1]. - The total funds raised from the IPO amounted to 1.501 billion yuan, with a net amount of 1.396 billion yuan after deducting issuance costs, which is 285 million yuan less than the original plan of 1.681 billion yuan [1]. - The funds were intended for various projects, including 182 million yuan for a vaccine project, 294 million yuan for a combined vaccine project, 163 million yuan for a nasal flu vaccine project, 177 million yuan for rabies and Hib vaccines, and 865 million yuan for R&D of in-progress products [1]. Group 2: Issuance Costs and Allocation - The total issuance costs for 百克生物 amounted to 105 million yuan, with the underwriting fees for the lead underwriter, CITIC Securities, and co-lead underwriter, Guotai Junan Securities, totaling 90.0406 million yuan [2]. - The final strategic placement of shares was 8.2561 million shares, accounting for 20% of the total issuance, with a minor adjustment of 744 shares redirected to offline issuance [2]. - CITIC Securities Investment Co., a subsidiary of the lead underwriter, received 1.6506 million shares, amounting to 60 million yuan [2].